BackImugene Limited Overview

Imugene Limited Receivables

Track Imugene Limited's receivables ($2.4M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$2.37M
↓ 76.32% YoYΔ $-7.65M vs prior year quarter

Peer trimmed avg / median

Loading

Imugene Limited Receivables History

Loading

Imugene Limited vs. peers: Receivables Comparison

Loading

Imugene Limited Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Imugene Limited (IMU.AX) FAQ

Imugene Limited's receivables stands at $2.4M as of June 2026. That compares with $10M in the prior-year period — down 76.3% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Imugene Limited reported $2.4M in receivables versus $10M a year earlier — a 76.3% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $10M in the prior-year period — down 76.3% year over year. Sustained growth in receivables can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Imugene Limited's receivables evolved across reporting periods, while the comparison chart places IMU.AX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, receivables is commonly used to spot outliers. Imugene Limited's reading of $2.4M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.

Questions & Answers